This clinical trial is focused on studying a condition called Autosomal Dominant Optic Atrophy (ADOA). ADOA is a genetic eye disease that affects the optic nerves, which are responsible for transmitting visual information from the eyes to the brain. The study will investigate a new treatment called STK-002, which is a type of medicine known as an antisense oligonucleotide. This treatment is designed to target specific genetic material related to the disease.

The purpose of the study is to evaluate the safety and tolerability of different doses of STK-002 in patients with ADOA. The study will also look at how the body processes the medicine after it is given as an injection into the eye, a method known as intravitreal use. Participants will receive single doses of the study medicine, and researchers will monitor them to gather information about the treatment’s effects and any potential side effects.

Throughout the study, various assessments will be conducted to understand the impact of the treatment on vision and eye health. These assessments include measuring the thickness of certain layers in the eye using a technique called optical coherence tomography (OCT), evaluating visual acuity, which is the clarity or sharpness of vision, and testing contrast sensitivity, which is the ability to distinguish between different shades of light and dark. Additionally, the study will assess the quality of life of participants using specific questionnaires. The trial is expected to continue until the end of 2026.